Sign In
Buy MNKD
$3.93
+0.0400 (+1.03%)
At Close: Jun 23, 2026
Collaboration underscores interest in inhaled insulin and strengthens bringing innovation and new options to pediatric diabetes care DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
Builds on recent FDA approval (May 29, 2026) of Afrezza for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes New data and real-world findings further emphasize p
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2
MannKind At An Inflection Point: Pediatric Expansion Drives The Story
10:40pm, Tuesday, 02'nd Jun 2026
MannKind gains FDA approval for Afrezza pediatric use, expanding its differentiated inhaled insulin therapy to children aged 6+ with type 1 or 2 diabetes. I see Afrezza's pediatric label extension as
MannKind Wins FDA Approval for Afrezza in Children, Opening Pediatric Diabetes Market
11:07pm, Saturday, 30'th May 2026
MannKind NASDAQ: MNKD said the U.S. Food and Drug Administration has approved Afrezza for pediatric patients with diabetes ages 6 and older, expanding the inhaled mealtime insulin's label into childre
MannKind Corporation (MNKD) Discusses FDA Approval of Afrezza for Pediatric Diabetes Patients Ages 6 and Older Transcript
07:24pm, Friday, 29'th May 2026
MannKind Corporation (MNKD) Discusses FDA Approval of Afrezza for Pediatric Diabetes Patients Ages 6 and Older Transcript
MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval
02:00pm, Friday, 29'th May 2026
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that management will host a conference call to discuss the recent FDA
US FDA approves MannKind's inhaled insulin for children
12:44pm, Friday, 29'th May 2026
The U.S. Food and Drug Administration has approved expanded use of MannKind's inhaled rapid-acting insulin in children with diabetes, offering patients under 18 years of age a needle-free tre
MannKind Announces FDA Approval of Afrezza® the 1st & Only Inhaled Mealtime Insulin for Use in Children & Adolescents Aged 6 and Older Living with Diabetes
MannKind to Present at Jefferies Global Healthcare Conference
04:00pm, Wednesday, 27'th May 2026
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that Chief Executive Officer, Michael Castagna, PharmD will partici
MANNKIND TO SHOWCASE NEW DATA AT ADA 2026 ADVANCING UNDERSTANDING OF INHALED INSULIN (AFREZZA®) IN PEDIATRIC CARE, PREGNANCY AND USE WITH AID SYSTEMS
The $59B Quiet Shift Reshaping How Patients Access Care
11:00am, Tuesday, 12'th May 2026
The $59B Quiet Shift Reshaping How Patients Access Care PR Newswire VANCOUVER, BC, May 12, 2026
MannKind Corporation (MNKD) Q1 2026 Earnings Call Transcript
01:01pm, Thursday, 07'th May 2026
MannKind Corporation (MNKD) Q1 2026 Earnings Call Transcript
MannKind: It's Complicated
12:50pm, Thursday, 07'th May 2026
MannKind Corporation remains a Hold, as revenue growth is increasingly reliant on niche assets like Furoscix and faces margin pressure. United Therapeutics' launch of Tresmi threatens MNKD's Tyvaso DP
